Chieh-ju Lee

Taipei, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.

Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.

Journal: Hepatology (Baltimore, Md.)
Published: April 09, 2025

Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.

Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.

Journal: BMC cancer
Published: March 31, 2025

Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.

Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.

Journal: JHEP reports : innovation in hepatology
Published: December 08, 2024

Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

Journal: Journal of hepatology
Published: January 04, 2024

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: January 26, 2023

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.

Journal: Cancer immunology, immunotherapy : CII
Published: November 17, 2021

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.

Journal: Hepatology communications
Published: August 03, 2021

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.

Journal: Therapeutic advances in medical oncology
Published: December 20, 2020

Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence.

Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence.

Journal: Cancers
Published: December 18, 2020

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.

Journal: Cancers
Published: June 18, 2020

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.

Journal: Cancers
Published: December 09, 2019

Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study.

Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study.

Journal: The Journal of infectious diseases
Published: February 10, 2018
Showing 1-12 of 12

Last Updated: 09/26/2026